Rare Disease Innovation and Partnering Summit
June 13-14, 2019 | Boston, MA
www.raredisease-summit.com
As genomics and advanced diagnostics expand our understanding of rare diseases, so too does the scope of impact expand. More than 30 million Americans live with a rare disease. While the industry has seen growth and heightened focus around the pursuit of orphan products and rare therapies, we’ve only scratched the surface.
CBI and EBD Group, along with support from the Alliance for Regenerative Medicine, Global Genes and MassBio, are pleased to announce the
Rare Disease Innovation and Partnering Summit, a platform designed to increase chances of therapeutic success for drug developers, patient groups and investors within the rare disease marketplace.
Business brings breakthroughs. Breakthroughs can transform lives.
Visit
www.raredisease-summit.com for further details and to register. Drug Channels readers will
save $300 off the standard rate when they use
discount code SFK676 and register prior to May 10th.*
Take a deep dive into the critical and evolving topics impacting you today and hear from industry thought leaders and patient advocates who have designed and led innovative approaches to complex challenges in driving curative progress.
You can download the complete agenda here. Take a look inside:
Real Life Case Examples:
- Develop New Models for Patient-Centric Registries – Parent Project Muscular Dystrophy
- Leverage Novel Collaborations in Orphan Drug Commercialization – Notable Labs and Cures Within Reach
- Mapping the Patient and Caregiver Journey – An Insights-Driven Approach to Building the Foundation of Patient Identification and Services – Rhythm Pharmaceuticals
PLUS! FDA Perspectives:
- Regulatory and Policy Update – Legislative Updates and New Initiatives within the FDA’s Orphan Drug Program
Featuring: Janet Maynard, MD, MHS, Director, Office of Orphan Products Development, FDA, Samir Shaikh, Deputy Director of Patient Affairs Staff, Office of Medical Products and Tobacco, FDA, Martine Zimmerman, Global Head, Regulatory Affairs, Alexion and John Hallinan, Chief Business Officer, Massachusetts Biotechnology Council
And! Benefit from Four Impactful Tracks:
- Patient-Driven Progress
- Reimbursement & Access
- New Launch & Commercialization
- Partnering & Investment
Additional perspectives and insight from 50+ leaders at companies such as Aegerion Pharmaceuticals, Alliance for Regenerative Medicine, Asklepios BioPharmaceuticals, Athersys, Bexion Pharmaceuticals, BioMarin, bluebird bio, Blueprint Medicines, Boston Children’s Hospital, Cotinga Pharmaceuticals, Cure CMT4J, Cydan II Inc., EveryLife Foundation for Rare Diseases, Geisinger, Global Genes, Horizon Pharma, Intercept Pharmaceuticals, Jackson Lab, Massachusetts General Hospital, MDA, Pfizer, Rare Access Action Project, Recordati Rare Diseases, Recursion Pharmaceutical, Sobi, Syros Pharmaceuticals, Tufts University School of Medicine, Xontogeny and more. Mark this as a must-attend event in 2019. Don’t miss it!
Visit
www.raredisease-summit.com for further details and to register. Drug Channels readers will
save $300 off the standard rate when they use
discount code SFK676 and register prior to May 10th.*
CBI and EBD Group will see you there!
Produced by: CBI and EBD Group
Supported by: Alliance for Regenerative Medicine, Global Genes and MassBio
*
Cannot be combined with other offers or used towards a current registration. Cannot be combined with special category rates, clinic/hospital rates, non-profit rates other offers. Other restrictions may apply.
The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.
